Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Global Forecast 2024-2030

Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Global Forecast 2024-2030


The Cell & Gene Therapy Biomanufacturing CDMO Market size was estimated at USD 338.12 million in 2023 and expected to reach USD 485.47 million in 2024, at a CAGR 32.53% to reach USD 2,428.90 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cell & Gene Therapy Biomanufacturing CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell & Gene Therapy Biomanufacturing CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.

Market Segmentation & Coverage


This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

Component
Cell Therapy
Plasmid DNA
Viral Vector
Phase
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Cancer
Cardiovascular Disease
Genetic Disorders
Infectious Disease
Neurological Disorders
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cell & Gene Therapy Biomanufacturing CDMO Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell & Gene Therapy Biomanufacturing CDMO Market?
3. What are the technology trends and regulatory frameworks in the Cell & Gene Therapy Biomanufacturing CDMO Market?
4. What is the market share of the leading vendors in the Cell & Gene Therapy Biomanufacturing CDMO Market?
5. Which modes and strategic moves are suitable for entering the Cell & Gene Therapy Biomanufacturing CDMO Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cell & Gene Therapy Biomanufacturing CDMO Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing number of R&D activities in cellular and genetic engineering and therapies
5.1.1.2. Increasing need for genetic treatments to cure chronic and genetic disorders
5.1.1.3. Rising number of collaborative activities between CDMOs and major players
5.1.2. Restraints
5.1.2.1. High cost of CDMO services
5.1.3. Opportunities
5.1.3.1. Efforts by CDMOs to incorporate digitalization and AI technologies
5.1.3.2. Rising number of biotechnology and pharmaceutical startups
5.1.4. Challenges
5.1.4.1. Complex regulations surrounding genetic and cell research
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component
6.1. Introduction
6.2. Cell Therapy
6.3. Plasmid DNA
6.4. Viral Vector
7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase
7.1. Introduction
7.2. Phase 1
7.3. Phase 2
7.4. Phase 3
7.5. Phase 4
8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication
8.1. Introduction
8.2. Cancer
8.3. Cardiovascular Disease
8.4. Genetic Disorders
8.5. Infectious Disease
8.6. Neurological Disorders
9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AGC Biologics
13.1.2. Almac Group
13.1.3. Becton, Dickinson and Company
13.1.4. Bio-Rad Laboratories, Inc.
13.1.5. Bio-Techne Corporation
13.1.6. Catalent Inc.,
13.1.7. Charles River Laboratories International Inc.
13.1.8. Danaher Corporation
13.1.9. Endress+Hauser Group Services AG
13.1.10. FUJIFILM Diosynth Biotechnologies
13.1.11. GC Corporation
13.1.12. General Electric Company
13.1.13. Getinge AB
13.1.14. Infors AG
13.1.15. Lonza Group Ltd
13.1.16. Merck KGaA
13.1.17. Miltenyi Biotec B.V. & Co. KG
13.1.18. Patheon Inc.
13.1.19. PCI Pharma Services
13.1.20. Pfizer CentreOne
13.1.21. PIERRE GUERIN
13.1.22. Recipharm AB
13.1.23. Samsung Biologics
13.1.24. Sartorius AG
13.1.25. Thermo Fisher Scientific
13.1.26. uBriGene
13.1.27. WuXi Advanced Therapies
13.1.28. WuXi AppTec
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET RESEARCH PROCESS
FIGURE 2. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2023 VS 2030
FIGURE 3. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET DYNAMICS
FIGURE 7. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
FIGURE 8. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
FIGURE 10. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings